Last updated: February 19, 2026
This analysis details the patent scope, claims, and surrounding landscape for Brazil patent BRPI0415853. The patent covers a specific crystalline form of Tamsulosin hydrochloride, identified as Form III. This crystalline form offers improved properties such as stability and dissolution rate compared to existing forms, potentially impacting the development and commercialization of generic Tamsulosin products in Brazil. The patent is currently active and will expire on December 9, 2024.
What is the Primary Subject of Patent BRPI0415853?
The core of patent BRPI0415853 is the protection of a specific crystalline form of Tamsulosin hydrochloride, designated as Form III. This polymorphic form is claimed for its distinct physical and chemical characteristics that offer advantages over other known crystalline forms of the same active pharmaceutical ingredient (API).
- Active Pharmaceutical Ingredient: Tamsulosin hydrochloride is an alpha-adrenergic receptor antagonist used primarily to treat the symptoms of benign prostatic hyperplasia (BPH) [1].
- Polymorphism: Different crystalline forms of the same compound are known as polymorphs. These polymorphs can exhibit different properties, including solubility, dissolution rate, bioavailability, and stability, which can affect drug formulation and efficacy [2].
- Form III: Patent BRPI0415853 specifically defines and claims Tamsulosin hydrochloride Form III. The patent describes characteristics of this form, including its X-ray powder diffraction (XRPD) pattern, differential scanning calorimetry (DSC) profile, and infrared (IR) spectroscopy data, which collectively differentiate it from other known forms [3].
What are the Key Claims of Patent BRPI0415853?
The patent's claims define the legal boundaries of its protection. For BRPI0415853, the claims focus on the specific crystalline Form III of Tamsulosin hydrochloride and its applications.
- Claim 1: This is the independent claim and typically defines the core invention. It claims Tamsulosin hydrochloride Form III, characterized by specific data from XRPD, DSC, or IR analysis. The precise defining characteristics (e.g., specific diffraction peaks, thermal events, or absorption bands) are critical to the claim's scope [3]. For example, a claim might specify the presence of certain characteristic peaks in the XRPD pattern at defined 2-theta angles.
- Dependent Claims: These claims narrow the scope of the independent claim by adding further limitations or specifying particular embodiments. For patent BRPI0415853, dependent claims might further specify:
- Tamsulosin hydrochloride Form III as defined in Claim 1, further characterized by a combination of XRPD, DSC, and IR data.
- Pharmaceutical compositions comprising Tamsulosin hydrochloride Form III.
- Methods of treating conditions such as benign prostatic hyperplasia (BPH) using pharmaceutical compositions containing Tamsulosin hydrochloride Form III [3].
What is the Scope of Protection for Tamsulosin Hydrochloride Form III?
The scope of protection granted by patent BRPI0415853 is determined by the wording of its claims. It extends to the specific crystalline Form III of Tamsulosin hydrochloride and potentially to pharmaceutical preparations and methods of treatment that utilize this specific form.
- Inclusion of Form III: Any Tamsulosin hydrochloride that exhibits the defining characteristics of Form III, as stipulated in the patent claims, falls within the scope of protection. This is critical for generic manufacturers who must ensure their Tamsulosin hydrochloride does not inadvertently produce or utilize Form III.
- Pharmaceutical Compositions: Claims covering pharmaceutical compositions extend protection to finished dosage forms (e.g., capsules, tablets) containing Tamsulosin hydrochloride Form III. This prevents the marketing of such formulations by competitors.
- Methods of Treatment: If the patent claims a method of treating a specific condition using Tamsulosin hydrochloride Form III, this can offer protection against the use of the drug for that purpose, regardless of the manufacturer.
What is the Current Status and Expiration Date of Patent BRPI0415853?
Understanding the patent's lifecycle is crucial for market entry strategies.
- Filing Date: December 9, 2004 [4].
- Grant Date: The patent was granted on September 12, 2017 [4].
- Current Status: Active.
- Expiration Date: December 9, 2024 [4]. This date marks the end of the patent's exclusivity period, after which Tamsulosin hydrochloride Form III would theoretically be in the public domain in Brazil.
What is the Significance of Tamsulosin Hydrochloride Form III's Properties?
The claimed advantages of Form III are central to the patent's inventiveness and market strategy. These properties can translate into improved drug products.
- Enhanced Stability: Improved chemical and physical stability of a crystalline form can lead to a longer shelf life and reduced degradation of the API during manufacturing and storage. This reduces the risk of product failure and ensures consistent dosage [2].
- Improved Dissolution Rate: A faster dissolution rate of the API from a dosage form generally leads to quicker absorption into the bloodstream, potentially resulting in a faster onset of therapeutic effect. For drugs like Tamsulosin, a rapid and consistent effect is desirable for managing BPH symptoms [2].
- Manufacturing Advantages: Specific crystalline forms may also offer advantages in drug formulation and manufacturing processes, such as better flowability or compressibility, leading to more efficient and cost-effective production [2].
Who is the Patent Holder for BRPI0415853?
The identity of the patent holder is essential for understanding who controls the intellectual property and who to engage with for licensing or potential challenges.
- Applicant/Assignee: Astellas Pharma Inc. [4]. Astellas Pharma is the original developer of Tamsulosin (marketed as Flomax in the US, Harnal in Japan, and Omnic in Europe and other regions) and holds significant patents related to this drug [5].
What is the Patent Landscape for Tamsulosin Hydrochloride in Brazil?
The patent landscape for Tamsulosin hydrochloride in Brazil involves multiple patents covering different aspects of the drug, including its API, formulations, and methods of use. Patent BRPI0415853 focusing on a specific crystalline form is one piece of this larger puzzle.
- Branded Product: The innovator drug, Tamsulosin hydrochloride, was originally developed and marketed by Astellas Pharma. The patent protection for the base molecule or earlier forms would have been filed and granted earlier.
- Polymorph Patents: BRPI0415853 exemplifies a strategy of seeking patent protection for specific crystalline forms of an established API. These "polymorph patents" can extend market exclusivity beyond the expiry of the original composition-of-matter patents [2].
- Generic Competition: As patents expire, generic manufacturers seek to enter the market. The existence of polymorph patents like BRPI0415853 can create barriers to entry for generics if their products utilize the patented form. Generic companies must navigate these patents, potentially by developing non-infringing polymorphs or challenging existing patents.
- Regulatory Exclusivities: In addition to patent protection, drug products may benefit from regulatory exclusivities granted by health authorities, which can provide additional market protection.
How Does Patent BRPI0415853 Intersect with Generic Tamsulosin Development?
The existence and claims of BRPI0415853 directly impact the strategies of companies seeking to market generic Tamsulosin hydrochloride in Brazil.
- Non-Infringing Formulations: Generic manufacturers must develop formulations that do not infringe on the patent claims. This primarily means avoiding the use of Tamsulosin hydrochloride Form III. They may need to research and identify alternative, non-infringing crystalline forms or develop amorphous forms of Tamsulosin hydrochloride.
- Patent Challenges: If a generic company believes that Form III is not novel or inventive, or if the claims are too broad, they may initiate legal proceedings to challenge the validity of patent BRPI0415853. Such challenges can be complex and expensive.
- Licensing Agreements: In some cases, a generic company might seek a license from the patent holder (Astellas Pharma) to utilize Form III, although this is less common if the intention is to offer a lower-cost generic alternative.
- Timing of Market Entry: The expiration date of December 9, 2024, is a key milestone. Generic companies will likely plan their market entry to coincide with or immediately follow this date, provided they have successfully navigated or circumvented any remaining patent protections.
What are the Potential Implications for the Brazilian Market?
The expiration of patent BRPI0415853, coupled with the specific nature of its claims, has several potential implications for the Brazilian pharmaceutical market.
- Increased Generic Availability: Upon expiration, the market for Tamsulosin hydrochloride in Brazil is likely to see increased competition from generic manufacturers who have developed non-infringing products. This can lead to lower prices for patients and healthcare providers.
- Pricing Pressure: The entry of multiple generic competitors will exert significant downward pressure on the prices of Tamsulosin hydrochloride products, benefiting the public health system and patients.
- Product Differentiation: Companies that successfully developed alternative, non-infringing crystalline forms or formulations may seek to differentiate their generic products based on unique properties or perceived advantages, even post-patent expiry.
- Innovation in Generic Development: The need to circumvent existing patents, particularly polymorph patents, can drive innovation in generic drug development, encouraging research into novel crystalline forms and advanced formulation techniques.
Key Takeaways
Patent BRPI0415853 protects Tamsulosin hydrochloride Form III, a specific crystalline form with potentially advantageous stability and dissolution properties. The patent is held by Astellas Pharma Inc. and is set to expire on December 9, 2024. This patent presents a significant hurdle for generic manufacturers intending to market Tamsulosin hydrochloride in Brazil, requiring them to develop non-infringing forms or formulations. Upon its expiration, the Brazilian market can anticipate increased generic competition, leading to potential price reductions and greater access to Tamsulosin hydrochloride treatments.
Frequently Asked Questions
-
Can generic Tamsulosin be sold in Brazil before December 9, 2024?
Generic Tamsulosin can be sold before December 9, 2024, only if the active pharmaceutical ingredient used by the generic manufacturer does not infringe on patent BRPI0415853. This means the generic must use a crystalline form other than Form III, or an amorphous form.
-
What happens if a generic company uses Tamsulosin hydrochloride Form III after the patent expires?
After December 9, 2024, generic companies are generally free to use Tamsulosin hydrochloride Form III, as the patent protection for this specific crystalline form will have ended.
-
Does patent BRPI0415853 cover all forms of Tamsulosin hydrochloride?
No, patent BRPI0415853 specifically covers crystalline Form III of Tamsulosin hydrochloride. It does not cover other crystalline forms, amorphous forms, or the Tamsulosin molecule itself if it was protected by earlier patents that have since expired.
-
Are there other patents protecting Tamsulosin hydrochloride in Brazil?
It is highly probable that other patents related to Tamsulosin hydrochloride, such as patents for the base molecule, specific formulations, or other polymorphs, exist or have existed in Brazil. A comprehensive landscape analysis would be required to identify all relevant patents.
-
What evidence is required to prove that a generic product uses a different crystalline form of Tamsulosin hydrochloride?
Manufacturers typically provide analytical data, such as X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and infrared (IR) spectroscopy, to demonstrate the crystalline form of their API. These data are compared against the defining characteristics of the patented form.
Citations
[1] Tamsulosin hydrochloride. (n.d.). National Center for Biotechnology Information. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Tamsulosin
[2] Crystalline polymorphism. (n.d.). U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/crystalline-polymorphism
[3] Brazilian Patent PI0415853-3 A. (2017). Instituto Nacional da Propriedade Industrial (INPI).
[4] Brazilian Patent PI0415853-3 A. (2017). Public search results, National Institute of Industrial Property of Brazil (INPI).
[5] Astellas Pharma Inc. (n.d.). Company Information. Retrieved from https://www.astellas.com/en/
